Literature DB >> 12537719

The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up.

Servaas A Morré1, Adriaan J C van den Brule, Lawrence Rozendaal, A Joan P Boeke, Feja J Voorhorst, Sjoerd de Blok, Chris J L M Meijer.   

Abstract

The natural course of asymptomatic Chlamydia trachomatis infections in women was studied during one year in a cohort based nested case-control study. Healthy women (n = 744, from four company health services in Amsterdam) with a medical check-up prior to job engagement were included. C. trachomatis-positive women (n = 30, cases) and a randomly selected control group of C. trachomatis-negative women (n = 186, controls) were followed for one year. Urine specimens (at one, six and 12 months) were analysed for the presence of C. trachomatis-DNA and the C. trachomatis-serovars, and questionnaires were filled in. The C. trachomatis prevalence and natural course in relation to demographic and sexual characteristics after one, six and 12 months were studied. The main outcome measures were 1) the prevalence of C. trachomatis using urine specimens; 2) self-reported complaints; 3) clinical symptoms reported to the coordinating physicians. The prevalence of asymptomatic C. trachomatis infections was 4% and there was no correlation with demographic and sexual characteristics. The person/year clearance rate was 44.7% per year. None of the C. trachomatis-positive women developed clinical symptoms or used C. trachomatis specific antibiotic treatment. Women with or without an asymptomatic infection had the same number of self-reported urogenital complaints during follow-up. In persisting infections twice as many C. trachomatis-serovar E infections were detected as compared to clearing infections. Our findings showed that almost half of the asymptomatic C. trachomatis infections in women cleared during one year of follow-up and none developed clinical pelvic inflammatory disease (PID), which is a much lower figure than previously suggested. Therefore these data are important for cost effectiveness calculations in screening programmes for asymptomatic C. trachomatis infections.

Entities:  

Mesh:

Year:  2002        PMID: 12537719     DOI: 10.1258/095646202762226092

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  57 in total

1.  Concomitant Chlamydia trachomatis and human papilloma virus infection cannot be attributed solely to sexual behaviour.

Authors:  V Verhoeven; M Baay; J Weyler; D Avonts; F Lardon; P Van Royen; J B Vermorken
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-18       Impact factor: 3.267

Review 2.  Human and Pathogen Factors Associated with Chlamydia trachomatis-Related Infertility in Women.

Authors:  S Menon; P Timms; J A Allan; K Alexander; L Rombauts; P Horner; M Keltz; J Hocking; W M Huston
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

Review 3.  Vaginal discharge.

Authors:  Des Spence; Catriona Melville
Journal:  BMJ       Date:  2007-12-01

4.  Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women's Cohort Study.

Authors:  N Low; M Egger; J A C Sterne; R M Harbord; F Ibrahim; B Lindblom; B Herrmann
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

5.  Cell Intrinsic Factors Modulate the Effects of IFNγ on the Development of Chlamydia trachomatis.

Authors:  Shardulendra Sherchand; Joyce A Ibana; Alison J Quayle; Ashok Aiyar
Journal:  J Bacteriol Parasitol       Date:  2016-07-25

6.  The cost effectiveness of opportunistic chlamydia screening in England.

Authors:  Elisabeth J Adams; Katherine M E Turner; W John Edmunds
Journal:  Sex Transm Infect       Date:  2007-07       Impact factor: 3.519

7.  Current crisis or artifact of surveillance: insights into rebound chlamydia rates from dynamic modelling.

Authors:  David M Vickers; Nathaniel D Osgood
Journal:  BMC Infect Dis       Date:  2010-03-16       Impact factor: 3.090

8.  Distribution study of Chlamydia trachomatis genotypes in symptomatic patients in Buenos Aires, Argentina: association between genotype E and neonatal conjunctivitis.

Authors:  Lucía Gallo Vaulet; Carolina Entrocassi; Ana I Corominas; Marcelo Rodríguez Fermepin
Journal:  BMC Res Notes       Date:  2010-02-09

9.  Community-based trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial.

Authors:  Pippa Oakeshott; Sally Kerry; Helen Atherton; Adamma Aghaizu; Sima Hay; David Taylor-Robinson; Ian Simms; Phillip Hay
Journal:  Trials       Date:  2008-12-10       Impact factor: 2.279

10.  Immunobiological outcomes of repeated chlamydial infection from two models of within-host population dynamics.

Authors:  David M Vickers; Qian Zhang; Nathaniel D Osgood
Journal:  PLoS One       Date:  2009-09-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.